Germany Issues Benefit Assessment For InterMune’s Esbriet, Despite Orphan Drug Status

Germany’s senior health technology assessment body, the G-BA, has said that InterMune’s Esbriet is beneficial, but says it is unsure to what extent. However, such added value assessments for orphan drugs could be illegal.